Info: Read More
  • 中药标准品生产商,产品定制服务
  • 睾酮

    Testosterone

    睾酮
    产品编号 CFN90034
    CAS编号 58-22-0
    分子式 = 分子量 C19H28O2 = 288.42
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Steroids
    植物来源 From male lobster serum and testes.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    睾酮 CFN90034 58-22-0 10mg QQ客服:2056216494
    睾酮 CFN90034 58-22-0 20mg QQ客服:2056216494
    睾酮 CFN90034 58-22-0 50mg QQ客服:2056216494
    睾酮 CFN90034 58-22-0 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Mysore (India)
  • Medical University of Gdansk (Poland)
  • University of Maryland (USA)
  • Research Unit Molecular Epigenetics (MEG) (Germany)
  • Universidade Católica Portuguesa (Portugal)
  • MTT Agrifood Research Finland (Finland)
  • The University of Newcastle (Australia)
  • Stanford University (USA)
  • University of Malaya (Malaysia)
  • University of British Columbia (Canada)
  • Mahatma Gandhi University (India)
  • Yale University (USA)
  • University of Indonesia (Indonesia)
  • Martin Luther University of Halle-Wittenberg (Germany)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Food Chem.2017, 228:301-314
  • J Cell Mol Med.2020, 24(21):12308-12317.
  • Evid Based Complement Alternat Med.2021, 8855980.
  • Front Microbiol.2021, 12:736780.
  • mBio.2020, 11(3):e00686-20.
  • Food Research International2020, 108987
  • PLoS One.2018, 13(11):e0208055
  • Free Radic Biol Med.2017, 112:191-199
  • Antioxidants (Basel).2021, 10(11):1831.
  • Separations2021, 8(6),80.
  • Environ Toxicol.2023, tox.23999.
  • Food Sci Biotechnol.2023, 32(9):1215-1223.
  • J Chromatogr A.2022, 1685:463640.
  • Cell Physiol Biochem.2019, 52(6):1255-1266
  • Nutrients.2020, 12(11):3448.
  • J Funct Foods2019, 54:449-456
  • J Cell Biochem.2018, 119(2):2231-2239
  • Phytother Res.2020, 34(4):788-795.
  • Pharmaceuticals.2022, 15(4), 402.
  • Int J Mol Sci.2019, 20(23):E6071
  • Advances in Traditional Medicine 2021, 21:779-789.
  • Front Chem.2023, 11:1245071.
  • Environ Toxicol.2020, doi: 10.1002
  • ...
  • 生物活性
    Description: Testosterone prevents pancreatic β-cell apoptosis due to glucotoxicity through reduction of the expression of ATGR1 and its signaling pathway.Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Testosterone can inhibit adipocyte differentiation in vitro through an AR-mediated nuclear translocation of beta-catenin and activation of downstream Wnt signaling.Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression.
    Targets: NADPH-oxidase | PDE | Wnt/β-catenin | Caspase | IL Receptor | gp120/CD4 | Androgen Receptor | ATGR1
    In vivo:
    Am J Physiol Heart Circ Physiol. 2015 Apr 1;308(7):H723-32.
    Association of testosterone with estrogen abolishes the beneficial effects of estrogen treatment by increasing ROS generation in aorta endothelial cells.[Pubmed: 25637546]
    Testosterone has been added to hormone replacement therapy to treat sexual dysfunction in postmenopausal women. Whereas estrogen has been associated with vascular protection, the vascular effects of testosterone are contradictory and the effects of its association with estrogen are largely unknown.
    METHODS AND RESULTS:
    In this study we determined the effects of testosterone associated with conjugated equine estrogen (CEE) on vascular function using a model of hypertensive postmenopausal female: ovariectomized spontaneously hypertensive rats. Female spontaneously hypertensive rats were divided into sham-operated, ovariectomized (OVX), and OVX treated for 15 days with either CEE alone (OVX+CEE) or associated with testosterone (OVX+CEE+T). Angiotensin II (ANG II)-induced contraction was markedly increased in aortic rings from OVX compared with sham-operated rats. CEE treatment restored ANG-II responses, a beneficial effect abrogated with CEE+T. CEE treatment also increased endothelium-dependent relaxation, which was impaired in OVX rats. This effect was lost by CEE+T. Treatment of aortas with losartan (ANG-II type-1 receptor antagonist) or apocynin (NADPH-oxidase inhibitor) restored the endothelium-dependent relaxation in OVX and CEE+T, establishing an interplay between ANG-II and endothelial dysfunction in OVX and CEE+T.
    CONCLUSIONS:
    The benefits by CEE were associated with downregulation of NADPH-oxidase subunits mRNA expression and decreased reactive oxygen species generation. The association of testosterone with CEE impairs the benefits of estrogen on OVX-associated endothelial dysfunction and reactive oxygen species generation in rat aorta by a mechanism that involves phosphorylation of the cytosolic NADPH-oxidase subunit p47(phox).
    J Sex Med. 2015 Apr;12(4):966-74.
    The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome.[Pubmed: 25648342]
    Both testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. This study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5 mg for erectile dysfunction with testosterone deficiency syndrome.
    METHODS AND RESULTS:
    Sixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000 mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20 mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5 mg during 30 weeks. Serological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. Total IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I.
    CONCLUSIONS:
    The combination of long-acting injectable TU and once-daily tadalafil 5 mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment.
    J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59.
    Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.[Pubmed: 20525905 ]
    Our objective was to update the guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.
    METHODS AND RESULTS:
    We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan.
    Eur J Endocrinol. 2006 Jun;154(6):899-906.
    Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.[Pubmed: 16728551 ]
    Testosterone therapy reduced the HOMA index (-1.73 +/- 0.67, P = 0.02, n = 14), indicating an improved fasting insulin sensitivity. Glycated haemoglobin was also reduced (-0.37 +/- 0.17%, P = 0.03), as was the fasting blood glucose (-1.58 +/- 0.68 mmol/l, P = 0.03). Testosterone treatment resulted in a reduction in visceral adiposity as assessed by waist circumference (-1.63 +/- 0.71 cm, P = 0.03) and waist/hip ratio (-0.03 +/- 0.01, P = 0.01). Total cholesterol decreased with testosterone therapy (-0.4 +/- 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed. CONCLUSIONS: Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Improvements in glycaemic control, insulin resistance, cholesterol and visceral adiposity together represent an overall reduction in cardiovascular risk.
    Circulation. 1999 Apr 6;99(13):1666-70.
    Acute anti-ischemic effect of testosterone in men with coronary artery disease.[Pubmed: 10190874]
    The role of testosterone on the development of coronary artery disease in men is controversial. The evidence that men have a greater incidence of coronary artery disease than women of a similar age suggests a possible causal role of testosterone. Conversely, recent studies have shown that the hormone improves endothelium-dependent relaxation of coronary arteries in men. Accordingly, the aim of the present study was to evaluate the effect of acute administration of testosterone on exercise-induced myocardial ischemia in men.
    METHODS AND RESULTS:
    After withdrawal of antianginal therapy, 14 men (mean age, 58+/-4 years) with coronary artery disease underwent 3 exercise tests according to the modified Bruce protocol on 3 different days (baseline and either testosterone or placebo given in a random order). The exercise tests were performed 30 minutes after administration of testosterone (2.5 mg IV in 5 minutes) or placebo. All patients showed at least 1-mm ST-segment depression during the baseline exercise test and after placebo, whereas only 10 patients had a positive exercise test after testosterone. Chest pain during exercise was reported by 12 patients during baseline and placebo exercise tests and by 8 patients after testosterone. Compared with placebo, testosterone increased time to 1-mm ST-segment depression (579+/-204 versus 471+/-210 seconds; P<0. 01) and total exercise time (631+/-180 versus 541+/-204 seconds; P<0. 01). Testosterone significantly increased heart rate at the onset of 1-mm ST-segment depression (135+/-12 versus 123+/-14 bpm; P<0.01) and at peak exercise (140+/-12 versus 132+/-12 bpm; P<0.01) and the rate-pressure product at the onset of 1-mm ST-segment depression (24 213+/-3750 versus 21 619+/-3542 mm Hgxbpm; P<0.05) and at peak exercise (26 746+/-3109 versus 22 527+/-5443 mm Hgxbpm; P<0.05).
    CONCLUSIONS:
    Short-term administration of testosterone induces a beneficial effect on exercise-induced myocardial ischemia in men with coronary artery disease. This effect may be related to a direct coronary-relaxing effect.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.4672 mL 17.3358 mL 34.6717 mL 69.3433 mL 86.6791 mL
    5 mM 0.6934 mL 3.4672 mL 6.9343 mL 13.8687 mL 17.3358 mL
    10 mM 0.3467 mL 1.7336 mL 3.4672 mL 6.9343 mL 8.6679 mL
    50 mM 0.0693 mL 0.3467 mL 0.6934 mL 1.3869 mL 1.7336 mL
    100 mM 0.0347 mL 0.1734 mL 0.3467 mL 0.6934 mL 0.8668 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    红苋甾酮; Rubrosterone CFN90840 19466-41-2 C19H26O5 = 334.4 5mg QQ客服:3257982914
    去氢表雄酮; Dehydroepiandrosterone CFN90043 53-43-0 C19H28O2 = 288.42 20mg QQ客服:215959384
    睾酮; Testosterone CFN90034 58-22-0 C19H28O2 = 288.42 20mg QQ客服:1413575084
    雌二醇; beta-Estradiol CFN90035 50-28-2 C18H24O2 = 272.38 20mg QQ客服:1457312923
    17α-雌二醇; 17alpha-Estradiol CFN96786 57-91-0 C18H24O2 = 272.38 5mg QQ客服:2056216494
    雌酚酮; Estrone CFN90042 53-16-7 C18H22O2 = 270.37 20mg QQ客服:1413575084
    固甾酮; Guggulsterone E&Z CFN93007 95975-55-6 C21H28O2 = 312.5 5mg QQ客服:3257982914

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产